U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257185) titled 'MHB018A Treatment in Patients With Chronic Thyroid Eye Disease' on Nov. 20.
Brief Summary: The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease (TED)
Intervention:
DRUG: MHB018A injection
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
DRUG: MHB018A injection Placebo
6 subcutaneous injections of MHB018A placebo once every ...